[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100423791":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":38,"locations":45,"responsibleParty":68,"collaborators":43,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":43,"enrollmentInfo":81,"targetDuration":43,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":47,"whyStopped":43,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Testosterone","EXPERIMENTAL","Intramuscular injections of testosterone undecanoate 750 mg.",[13],"Drug: Testosterone Undecanoate 250 MG\u002FML",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Intramuscular injections of placebo.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Testosterone Undecanoate 250 MG\u002FML","Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.",[9],[9],{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Intramuscular administration of placebo at baseline, weeks 4, and week 14.",[15],[31],"Control",[33,36],{"name":34,"affiliation":5,"role":35},"Shehzad Basaria, MD","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":5,"role":35},"Robert R Edwards, PhD",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Julia Crosby","CONTACT","617-525-6726",null,"jpcrosby@bwh.harvard.edu",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-71.05977,42.35843,{"lat":57,"lon":56},[60,61,62,63,66],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},{"name":34,"role":35,"phone":43,"phoneExt":43,"email":43},{"name":37,"role":35,"phone":43,"phoneExt":43,"email":43},{"name":64,"role":65,"phone":43,"phoneExt":43,"email":43},"Vitaly Napadow, PhD","SUB_INVESTIGATOR",{"name":67,"role":65,"phone":43,"phoneExt":43,"email":43},"Thomas G Travison, PhD",{"type":35,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Shehzad Basaria, M.D.","Professor of Medicine, Harvard Medical School; Associate Director, Section on Men's Health, Aging & Metabolism, Brigham and Women's Hospital","100423791","phase-2-pain-alleviation-with-testosterone-in-opioid-induced-hypogonadism-100423791",false,"NCT04798469","Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism","Androgen Replacement to Improve Patient-Important Outcomes in Men With Opioid-Induced Hypogonadism","PATH","Inclusion Criteria:\n\n* Men, age 18 years and older.\n* Chronic non-cancer spinal pain.\n* Use of opioid analgesics for at least 6 months.\n* Serum total testosterone (measured by mass spectrometry) \\\u003C348 ng\u002FdL and\u002For free testosterone \\\u003C70 pg\u002FmL.\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* History of prostate cancer or breast cancer.\n* Known history of organic hypogonadism (e.g., due to hypothalamic, pituitary or testicular disease).\n* Use of testosterone within the past 6 months.\n* Baseline hematocrit \\>48%.\n* Prostate-specific antigen (PSA) level \\>4 ng\u002FmL in Caucasians or \\>3 ng\u002FmL in African-Americans.\n* Presence of prostate nodule or induration on digital rectal examination.\n* Uncontrolled congestive heart failure.\n* Myocardial infarction, acute coronary syndrome, revascularization surgery or stroke within 3 months.\n* Serum creatinine \\>2.5 mg\u002FdL.\n* Alanine aminotransferase (ALT) level 3 times above the upper limit of normal.\n* Diagnosis of bipolar disorder or schizophrenia.\n* Presence of metallic implants (pacemakers, aneurysm clips, etc.) that preclude the patient from undergoing functional magnetic resonance imaging (MRI). In subjects who are otherwise eligible and either do not qualify for MRI or are reluctant to undergo imaging, the investigators may consider enrolling such participants on a case-by-case basis.","MALE","18 Years",{"count":82,"type":83},150,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism (low testosterone).",[89,90,91],"Opioid Use","Pain","Hypogonadism, Male",[90,93,9],"Opioid Analgesics","2026-04-11",{"date":96,"type":97},"2026-04-14","ACTUAL",{"date":99,"type":97},"2022-01-10",{"date":101,"type":83},"2027-12-30",{"name":5,"class":6},1]